Table 5. Effect of zinc supplementation on severity of migraine attacks and MIDAS among patients with migraine attacks.
| Variable | Time | Group | Negligible | Mild | Moderate | Severe | p value‡ |
|---|---|---|---|---|---|---|---|
| Migraine attacks severity* | Baseline | Zinc group | - | 3.80 (1) | 42.30 (11) | 53.80 (14) | 0.651 |
| Placebo group | - | 10.70 (3) | 32.10 (9) | 57.10 (16) | |||
| Treatment 2nd month | Zinc group | - | 76.90 (20) | 23.10 (6) | - | 0.046 | |
| Placebo group | - | 50.00 (14) | 50.00 (14) | - | |||
| Treatment 3rd month | Zinc group | - | 100.00 (26) | - | - | < 0.001 | |
| Placebo group | - | 3.60 (1) | 21.40 (6) | 75.00 (21) | |||
| MIDAS† | Baseline | Zinc group | 23.10 (6) | 30.80 (8) | 23.10 (6) | 23.10 (6) | |
| Placebo group | 14.30 (4) | 25.00 (7) | 42.90 (12) | 17.90 (5) | |||
| Treatment 3rd month | Zinc group | 76.90 (20) | 23.10 (6) | 0.00 (0) | 0.00 (0) | < 0.001 | |
| Placebo group | 3.60 (1) | 28.60 (8) | 21.40 (6) | 50.00 (14) |
Data are shown as percent (number).
MIDAS, migraine disability assessment.
*Mild:(1–4), moderate:(4–6), severe:(6–10); †Negligible:(0–5), mild:(6–10), moderate:(11–20), severe:(> 21); ‡The χ2 test were performed.